Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

34.6%

9 terminated/withdrawn out of 26 trials

Success Rate

64.0%

-22.5% vs industry average

Late-Stage Pipeline

46%

12 trials in Phase 3/4

Results Transparency

19%

3 of 16 completed trials have results

Key Signals

3 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2

12(46.2%)

Phase 3

11(42.3%)

Phase 1

2(7.7%)

Phase 4

1(3.8%)

26Total

Phase 2(12)

Phase 3(11)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT02279498Phase 3Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Role: lead

NCT02823964Phase 4Completed

EASY: Extended Access to Sollpura Over Years

Role: lead

NCT02734810Phase 3Completed

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Role: lead

NCT03051490Phase 3Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Role: lead

NCT02062684Phase 2Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Role: lead

NCT02514967Phase 3Terminated

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Role: lead

NCT01395745Phase 3Completed

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Role: lead

NCT02074020Phase 3Withdrawn

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Role: lead

NCT01598857Phase 2Withdrawn

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

Role: lead

NCT02052219Phase 3Withdrawn

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Role: lead

NCT01609452Phase 2Withdrawn

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Role: lead

NCT00449904Phase 3Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase

Role: lead

NCT00500084Phase 3Terminated

Phase III ALTU-135 CP Safety Trial

Role: lead

NCT00449878Phase 3Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Role: lead

NCT00095732Phase 2Completed

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Role: lead

NCT00434473Phase 2Completed

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

Role: lead

NCT01162681Phase 2Completed

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Role: lead

NCT01522196Phase 2Terminated

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

Role: lead

NCT00743925Phase 2Completed

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes

Role: lead

NCT01305746Phase 2Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Role: lead